JP2022551254A - ヒト免疫不全ウイルスの複製阻害剤 - Google Patents

ヒト免疫不全ウイルスの複製阻害剤 Download PDF

Info

Publication number
JP2022551254A
JP2022551254A JP2022520234A JP2022520234A JP2022551254A JP 2022551254 A JP2022551254 A JP 2022551254A JP 2022520234 A JP2022520234 A JP 2022520234A JP 2022520234 A JP2022520234 A JP 2022520234A JP 2022551254 A JP2022551254 A JP 2022551254A
Authority
JP
Japan
Prior art keywords
methyl
chloro
ethyl
difluoromethyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551254A5 (enExample
Inventor
マイケル、エス．ボウシャー
エリック、ピー、ギリス
クリスティアナ、イワグウ
ビー．ナラシムフル、ナイドゥ
カイル、イー．パーセラ
マノイ、パテル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2022551254A publication Critical patent/JP2022551254A/ja
Publication of JP2022551254A5 publication Critical patent/JP2022551254A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022520234A 2019-10-01 2020-09-29 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2022551254A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962908715P 2019-10-01 2019-10-01
US62/908,715 2019-10-01
US201962925300P 2019-10-24 2019-10-24
US62/925,300 2019-10-24
PCT/IB2020/059103 WO2021064571A1 (en) 2019-10-01 2020-09-29 N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2022551254A true JP2022551254A (ja) 2022-12-08
JP2022551254A5 JP2022551254A5 (enExample) 2023-10-10

Family

ID=72811913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520234A Pending JP2022551254A (ja) 2019-10-01 2020-09-29 ヒト免疫不全ウイルスの複製阻害剤

Country Status (4)

Country Link
US (1) US20220389007A1 (enExample)
EP (1) EP4038068A1 (enExample)
JP (1) JP2022551254A (enExample)
WO (1) WO2021064571A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551691A (ja) * 2019-10-08 2022-12-13 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20250042926A1 (en) * 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504392A (ja) * 2013-01-09 2016-02-12 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体
WO2018203235A1 (en) * 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504392A (ja) * 2013-01-09 2016-02-12 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体
WO2018203235A1 (en) * 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551691A (ja) * 2019-10-08 2022-12-13 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤

Also Published As

Publication number Publication date
EP4038068A1 (en) 2022-08-10
WO2021064571A1 (en) 2021-04-08
US20220389007A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JP7088983B2 (ja) キナーゼ阻害剤としてのビアリールアミド化合物
TWI824041B (zh) 人類免疫缺乏病毒複製之抑制劑
JP2022551254A (ja) ヒト免疫不全ウイルスの複製阻害剤
JP6923543B2 (ja) Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール
CA2900748C (en) Novel pyrimidine and pyridine compounds and their usage
WO2019198024A1 (en) 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
ES2974657T3 (es) Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
EP3849982A1 (en) Inhibitors of human immunodeficiency virus replication
EP4041729B1 (en) Inhibitors of human immunodeficiency virus replication
EP4038061A1 (en) Inhibitors of human immunodeficiency virus replication
CA3170536A1 (en) Inhibitors of human immunodeficiency virus replication
RU2812128C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA043730B1 (ru) Ингибиторы репликации вируса иммунодефицита человека
HK40060467B (en) Inhibitors of human immunodeficiency virus replication
HK40060467A (en) Inhibitors of human immunodeficiency virus replication

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250131